Investor Presentaiton

ORIENT-32 (1L HCC): Global First PD-1 Combination Study that Met Primary Endpoints Overall Survival (%) 100 75 50 OS 62.4% 48.5% Arms Events, n (%) 25 Median OS (mo) (95% CI) HR P value ab (95% CI)* Sin + Bev 122 (32.1) NE (NE, NE) <0.0001 0.569 (0.431, 0.751) Sor 87 (45.5) 10.4 (8.5, NE) Progression-free Survival (%) PFS (by IRRC) Arms Events, n (%) Median PFS (mo) (95% CI) P value & b HR (95% CI)* Sin + Bev 245 (64.5) 4.6 (4.1, 5.7) 0.565 <0.0001 (0.455, 0.701) Sor 142 (74.3) 2.8 (2.7, 3.2) 43.6% 32.7% 19.5% M AMA :11.6% 0 2 4 6 8 Months 10 12 14 16 0 2 4 6 8 10 12 14 Months Number at risk Sin + Bev 380 372 351 Sor 191 175 153 314 132 235 95 126 50 52 57 11 22 2 0 0 Number at risk SinBev 380 Sor 191 267 111 197 55 144 89 37 7 24 13 4 1 0 Sintilimab in combination with BYVASDAⓇ (bevacizumab biosimilar): the global first PD-1 combo study that met primary endpoints with significant improvement in both OS and PFS for 1L HCC Proffered Paper presentation VIRTUAL 2020 ESMO ASIA at the ESMO Asia Virtual Congress 2020 ESMO ASIA 2020 VIRTUAL Innovent 20-22 NOVEMBER 2020 Confidential Copyright©2021 Innovent Biologics 19

View entire presentation